Divas Neupane1, Murray Korc. 1. Department of Medicine and Pharmacology and Toxicology, Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Hanover, New Hamsphire 03756, USA.
Abstract
PURPOSE: The purpose of the present study was to investigate the potential role of 14-3-3sigma in pancreatic ductal adenocarcinoma (PDAC). EXPERIMENTAL DESIGN: 14-3-3 isoform expression was determined by real-time quantitative PCR in laser capture normal pancreatic ductal cells and pancreatic cancer cells and in 5 pancreatic cancer cell lines. PANC-1 cells, with low levels of 14-3-3sigma, were stably transfected with a human 14-3-3sigma cDNA. Conversely, high endogenous 14-3-3sigma levels in T3M4 cells were suppressed by specific short hairpin RNA. Apoptosis, motility, and invasiveness were studied. RESULTS: The cancer cells in 7 PDAC samples expressed high levels of 14-3-3sigma mRNA by quantitative PCR when compared with normal pancreatic duct cells. 14-3-3sigma protein levels were high in BxPC3, COLO-357, and T3M4 cells, intermediate in ASPC-1 cells, and low in PANC-1 cells. Most cell lines released detectable amount of 14-3-3sigma into conditioned medium. Overexpression of 14-3-3sigma in PANC-1 cells led to resistance to cisplatinum-induced apoptosis, increased basal migration, and increased invasion in response to epidermal growth factor and insulin-like growth factor-I. By contrast, short hairpin RNA-mediated knockdown of endogenous 14-3-3sigma in T3M4 cells did not alter migration but led to enhanced cisplatinum sensitivity, increased invasiveness in response to epidermal growth factor, and decreased invasiveness in response to insulin-like growth factor-I. CONCLUSIONS: 14-3-3sigma contributes to the chemoresistance of pancreatic cancer cells and exerts cell type-dependent effects on cell migration and invasion. Therefore, strategies aimed at suppressing 14-3-3sigma expression and function may have a therapeutic benefit in subgroups of patients with PDAC.
PURPOSE: The purpose of the present study was to investigate the potential role of 14-3-3sigma in pancreatic ductal adenocarcinoma (PDAC). EXPERIMENTAL DESIGN: 14-3-3 isoform expression was determined by real-time quantitative PCR in laser capture normal pancreatic ductal cells and pancreatic cancer cells and in 5 pancreatic cancer cell lines. PANC-1 cells, with low levels of 14-3-3sigma, were stably transfected with a human14-3-3sigma cDNA. Conversely, high endogenous 14-3-3sigma levels in T3M4 cells were suppressed by specific short hairpin RNA. Apoptosis, motility, and invasiveness were studied. RESULTS: The cancer cells in 7 PDAC samples expressed high levels of 14-3-3sigma mRNA by quantitative PCR when compared with normal pancreatic duct cells. 14-3-3sigma protein levels were high in BxPC3, COLO-357, and T3M4 cells, intermediate in ASPC-1 cells, and low in PANC-1 cells. Most cell lines released detectable amount of 14-3-3sigma into conditioned medium. Overexpression of 14-3-3sigma in PANC-1 cells led to resistance to cisplatinum-induced apoptosis, increased basal migration, and increased invasion in response to epidermal growth factor and insulin-like growth factor-I. By contrast, short hairpin RNA-mediated knockdown of endogenous 14-3-3sigma in T3M4 cells did not alter migration but led to enhanced cisplatinum sensitivity, increased invasiveness in response to epidermal growth factor, and decreased invasiveness in response to insulin-like growth factor-I. CONCLUSIONS:14-3-3sigma contributes to the chemoresistance of pancreatic cancer cells and exerts cell type-dependent effects on cell migration and invasion. Therefore, strategies aimed at suppressing 14-3-3sigma expression and function may have a therapeutic benefit in subgroups of patients with PDAC.
Authors: T Samuel; H O Weber; P Rauch; B Verdoodt; J T Eppel; A McShea; H Hermeking; J O Funk Journal: J Biol Chem Date: 2001-09-26 Impact factor: 5.157
Authors: A T Ferguson; E Evron; C B Umbricht; T K Pandita; T A Chan; H Hermeking; J R Marks; A R Lambers; P A Futreal; M R Stampfer; S Sukumar Journal: Proc Natl Acad Sci U S A Date: 2000-05-23 Impact factor: 11.205
Authors: N Iwata; H Yamamoto; S Sasaki; F Itoh; H Suzuki; T Kikuchi; H Kaneto; S Iku; I Ozeki; Y Karino; T Satoh; J Toyota; M Satoh; T Endo; K Imai Journal: Oncogene Date: 2000-11-02 Impact factor: 9.867
Authors: Nijaguna B Prasad; Jeanne Kowalski; Hua-Ling Tsai; Kristin Talbot; Helina Somervell; Guennadi Kouniavsky; Yongchun Wang; Alan P B Dackiw; William H Westra; Douglas P Clark; Steven K Libutti; Christopher B Umbricht; Martha A Zeiger Journal: Thyroid Date: 2012-01-26 Impact factor: 6.568
Authors: Sripathi M Sureban; Randal May; Stan A Lightfoot; Aimee B Hoskins; Megan Lerner; Daniel J Brackett; Russell G Postier; Rama Ramanujam; Altaf Mohammed; Chinthalapally V Rao; James H Wyche; Shrikant Anant; Courtney W Houchen Journal: Cancer Res Date: 2011-02-01 Impact factor: 12.701
Authors: Fang Fang; Horacio Cardenas; Hao Huang; Guanglong Jiang; Susan M Perkins; Chi Zhang; Harold N Keer; Yunlong Liu; Kenneth P Nephew; Daniela Matei Journal: Cancer Res Date: 2017-12-11 Impact factor: 12.701